Allergen-specific immunotherapy offers a disease-modifying approach to canine atopic dermatitis, potentially providing long-term improvement compared to lifelong symptomatic treatment.
Canine atopic dermatitis is a chronic, lifelong condition where current symptomatic treatments provide relief but do not alter the underlying allergic disease. Allergen-specific immunotherapy represents the only treatment option that genuinely modifies the immune response driving the disease. The welfare benefit of successful ASIT - sustained reduction in itch severity, reduced medication burden, and improved quality of life - is substantial compared to lifelong dependency on immunosuppressive drugs with their cumulative side effect profile. The commitment required (regular allergen administration for 12-18 months before full benefit is apparent, followed by ongoing maintenance) is significant, but the long-term welfare return for good responders justifies this investment. Dogs that achieve ASIT remission can often reduce or eliminate other medications while maintaining much lower itch severity.